Slide 1: Future Proof Healthcare
FUTURE PROOF HEALTHCARE A sustainable healthcare for a new generation Presentation Q4(21) Jonas Jarvius, CEO Anders Lundin, CFO/IR
Slide 2: Disclaimer
Disclaimer DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS
Slide 3: Q-linea 4th quarter: Introduction to the company
Headquarters, Marketing and demo lab, Consumable production in Uppsala Q-linea 4th quarter Q-linea is developing disruptive solutions for faster Lead product ASTar® infectious disease diagnostics, first product targeting sepsis Introduction to the company 173 employees & consultants at year end Achi
Slide 4: Sepsis – a global health crisis
Sepsis – a global health crisis Time to correct treatment critical for patient outcome 4
Slide 5: Why is improved infectious disease diagnostics important?
Why is improved infectious disease diagnostics important? Sepsis AMR Antimicrobial Resistance Leading cause of death in U.S. hospitals1) Has been presented as #1 hospitalization cost in the US with over $24bn “The biggest threat to mankind” yearly3) Rapid diagnostics would reduce Kills >500,000 peop
Slide 6: Rapid AST & a broad antimicrobial panel matters
Rapid AST & a broad antimicrobial panel matters: ASTar can provide up to 48 hours faster actionable results DAY 1 DAY 2 DAY 3 DAY 4 Plates are streaked CURRENT WORKFLOW Gram Susceptibility Patient to perform a Colony blood draw stain clean culture selection Determination (AST) Optimized Time to Bloo
Slide 7: Health economic benefits of 24 hour faster diagnostics
Health economic benefits of 24 hour faster diagnostics Less pressure for Cost savings Lower mortality resistance and superinfections Up to 25% Up to 40% ~$2,500 – $20,000 reduction of C. difficile lower mortality rates1) cost savings per patient3) infections2) ASTar can provide up to 48 hours faster
Slide 8: ASTar – a platform designed to save lifetimes
ASTar – a platform designed to save lifetimes Developed together with our future customers Easy to use Comprehensive • Fully automated • Large antibiotic panel • ~2 min hands-on time • Long concentration • Load-and go workflow ranges • Fastidious and non- fastidious bacteria Fast • Support additiona
Slide 9: Easy to use
Easy to use User friendly & 24/7 availability ASTar enables anyone at the lab to load sample anytime and enables lab personnel to do more in less time Click “start” Scan barcode Add sample Load AST disc Add sample barcode Click “Start run” Source: Company information and webpage 9
Slide 10: ASTar provides excellent performance
ASTar provides excellent performance Broadest panel enabling actionable results Excellent and accurate data from the CE-IVD clinical study FDA and ISO requirements1,2) The ASTar® Instrument and ASTar® BC G- Kit offer the Essential agreement = Same MIC value as reference broadest combination of antim
Slide 11: High throughput and flexible solution
High throughput and flexible solution High throughput & flexible Our ambition was the most user friendly and capable system Up to 12 patient samples in parallel = Fully automatic Semi automatic Consumables stored at room temp and a small insert at -20°C. Compatible with small and large (e.g. urine)
Slide 12: Excellent results from extensive commercial evaluation
Excellent results from extensive commercial evaluation ASTar performed very well with great customer feedback Evaluation performed by Thermo Fisher Scientific™ with support from Q-linea Customer sites performed ASTar testing on G- BC+ patient samples in parallel to their current testing Almost 500 d
Slide 13: Key highlights fourth quarter
Key highlights fourth quarter Strong results from commercial evaluation performed by Q-linea in Sweden Evaluation performed at a Swedish Regional Hospital Overall Essential Agreement (EA) = 96,3% The study included approximately 30 patients Patient samples included both non-fastidious and fastidious
Slide 14: Patient case report Swedish evaluation
Key highlights fourth quarter Patient – case report Swedish evaluation, ASTar makes a difference… 14 14 Source: Company information.
Slide 15: Key highlights fourth quarter: US clinical study
Key highlights fourth quarter US clinical study entered final stage Prospective study started Three US hospitals included in the prospective study Enrollment started in December Slight delays initially because of Covid After period end The preparation of the 510k application started Initial data rev
Slide 16: Active presentation of ASTar by Thermo Fisher Scientific
Key highlights fourth quarter Active presentation of ASTar by Thermo Fisher Scientific Since launch in October an active period with customer visits & trade shows started Thermo Fisher Scientific presented ASTar on two trade shows • KMIS ( Virtual) 2-4 Dec • RICAI Paris 13-14 Dec Strong interest fro
Slide 17: Strong interest from the market but long sales processes
Key highlights fourth quarter Strong interest from the market but long sales processes Thermo Fisher Scientific is actively marketing ASTar with a large team Strong interest from customers Large and continuously growing sales funnel Several evaluations ongoing and are in the planning Some evaluation
Slide 18: Key highlights after period end
Key highlights after period end ASTar´s value proposition further strengthen ASTar already provided the broadest combination of antimicrobials and dilution ranges in a single analysis for Gram-negative bacteria. Our goal has always been to enable as many patients as possible to receive faster time t
Slide 19: The effects of the Corona pandemic on Q-linea
The effects of the Corona pandemic on Q-linea Moving back to normal operation Finally, we are now all moving back to the new normal after the pandemic Our conclusion is that Q-linea and its personnel has managed the pandemic in a good way No identified spread within the company Rapid follow up and i
Slide 20: Income statement fourth quarter
Income statement fourth quarter Net sales in the fourth quarter amounted to SEK 3.9 million (0.0). Goods that have been expensed in the fourth amounted SEK -3.4 (0) million. Operating result totalled SEK -51.6 million (-57.1). The company reported a loss after tax of SEK -51.0 million (-56.6). Earni
Slide 21: Balance sheet at the end of fourth quarter
Balance sheet at the end of fourth quarter Cash and cash equivalents amounted to SEK 15.1 million (10.1) Short-term investments in fixed-income funds SEK 91,2 million (165,7) and the current portion of non-current assets (listed bonds) SEK 59.7 million (131.0). Non-current assets, listed bonds SEK 1
Slide 22: Cash flow statement fourth quarter
Cash flow statement fourth quarter Cash flow from operating activities SEK -90.9 million (-76.7). Increase in cash outflow from operating activities mainly due to changes in the working capital compared to the same quarter last year. Cash flow from investing activities SEK 84.4 million (69.1). Net d
Slide 23: Thank you
Looking forward to an exciting continuation of 2022 Q-linea wants to contribute to a healthier society by future- proofing a new generation of healthcare professionals, labs and hospitals. Thank you 23